

American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-0545 bloodadvances@hematology.org

Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria

Tracking no: ADV-2024-012672R2

Régis Peffault de Latour (French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, France) Morag Griffin (St James's University Hospital, United Kingdom) Richard Kelly (St James's University Hospital, United Kingdom) Jeff Szer (Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Australia) Carlos de Castro (Duke University School of Medicine, United States) Regina Horneff (Swedish Orphan Biovitrum AB, Sweden) Lisa Tan (Swedish Orphan Biovitrum AB, United Kingdom) Michael Yeh (Apellis Pharmaceuticals, Inc., Waltham, MA, USA., United States) Jens Panse (Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen; Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany)

Abstract:

Patients with paroxysmal nocturnal hemoglobinuria (PNH) experience complement-mediated intravascular hemolysis leading to anemia, fatigue, and potentially life-threatening thrombotic complications. Pegcetacoplan, a C3 inhibitor, demonstrated sustained improvements in hematological and clinical parameters in the Phase 3 PEGASUS trial in patients with PNH who remained anemic despite C5 inhibitor therapy. The current post-hoc analysis describes 26 hemolysis adverse events (AEs) experienced in 19 patients during pegcetacoplan therapy in PEGASUS and baseline patient characteristics potentially associated with increased hemolysis risk. Lactate dehydrogenase (LDH) {greater than or equal to}2× the upper limit of normal (ULN) was observed in 19 events, including 2 with LDH {greater than or equal to}10× ULN. All patients experienced decreased hemoglobin during hemolysis (mean decrease: 3.0 g/dL). In 16 events (62%) a potential complement-amplifying condition underlying the event could be identified. Hemolysis AEs led to study discontinuation in 5 patients. However, 17 of 26 (65%) hemolysis AEs were manageable without pegcetacoplan discontinuation. A greater proportion of patients with hemolysis AEs (n=19) had key characteristics of higher disease activity at baseline compared to patients without hemolysis AEs (n=61), namely higher-than-label eculizumab dose (53% vs 23%), detectable CH50 (74% vs 54%) and {greater than or equal to}4 transfusions in the previous 12 months (68% vs 51%). These characteristics may be useful predictors of potential future hemolysis events. ClinicalTrials.gov identifier: NCT03500549

Conflict of interest: COI declared - see note

COI notes: R. Peffault de Latour reports consultancy, honoraria, research funding with Alexion, Novartis, and Pfizer; research funding with Amgen; and consultancy and honoraria with Apellis Pharmaceuticals and Swedish Orphan Biovitrum AB. M. Griffin reports consultancy with BioCryst, Regeneron, and Swedish Orphan Biovitrum AB, speaker's fees from Alexion, AstraZeneca, Novartis, and Swedish Orphan Biovitrum AB, scientific advisory board member for Alexion, AstraZeneca, BioCryst, and Novartis. R.J. Kelly reports research support from Novartis and Swedish Orphan Biovitrum AB, consultancy with Swedish Orphan Biovitrum AB, speaker's fees from Alexion, Swedish Orphan Biovitrum AB, Jazz, Astellas, Otsuka, Amgen, Novartis and Biologix, scientific advisory board member for Alexion, Swedish Orphan Biovitrum AB, Jazz, Abbvie, Novartis and Roche. J. Szer reports research support from Alexion, Apellis Pharmaceuticals, Novartis, Ra Pharma, Sanofi-Genzyme, consultancy with Biocryst, speaker's fees from Alexion, Novartis, Swedish Orphan Biovitrum AB, scientific advisory board member for Link Pharmaceuticals, Novartis, Sanofi-Genzyme, Swedish Orphan Biovitrum AB. C. de Castro reports research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals, consultancy at Apellis Pharmaceuticals, honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals. R. Horneff is currently employed by Swedish Orphan Biovitrum AB and hold company shares. L. Tan is a consultant to Swedish Orphan Biovitrum AB. M. Yeh is currently employed by Apellis Pharmaceuticals, Inc. and hold company shares. J. Panse reports consultancy, honoraria, membership on an entity's Board of Directors or advisory committees with Apellis Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Grunenthal, and MSD; consultancy, membership on an entity's Board of Directors or advisory committees with Amgen; speakers bureau with Chugai and Pfizer; and membership on an entity's Board of Directors or advisory committees, speakers bureau with Alexion, Boehringer Ingelheim and Novartis.

Preprint server: No;

Author contributions and disclosures: The study was designed by the sponsor (Apellis Pharmaceuticals) and the academic authors. Trial investigators collected the data. R.P.L., M.G., R.J.K., J.S., C.C. R.H., L.T., M.Y, and J.P. (all authors) contributed to the analysis or interpretation of the data as well as revision of the manuscript. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol. Manuscript review was conducted by Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals during the development process. Full editorial control of the manuscript was maintained by the authors, all of whom provided their final approval of the manuscript submitted for publication.

Non-author contributions and disclosures: Yes; Medical writing support was provided by Miriam Souto and Colin Plumb, nspm ltd., funded by Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals.

Agreement to Share Publication-Related Data and Data Sharing Statement: Data access will be granted in response to qualified research requests. Individual participant data will not be shared. All requests are evaluated by a cross functional panel of experts within Sobi, and a decision on sharing will be based on the scientific merit and feasibility of the research proposal, maintenance of personal integrity, and commitment to publication of the results. To request access to study data, a data sharing request form (available on www.sobi.com) should be sent to medical.info@sobi.com.

Clinical trial registration information (if any): ClinicalTrials.gov identifier: NCT03500549 https://classic.clinicaltrials.gov/ct2/show/NCT03500549

Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria

Short title: Hemolysis events in the Phase 3 PEGASUS study

Régis Peffault de Latour¹, Morag Griffin², Richard J Kelly², Jeff Szer³, Carlos de Castro⁴, Regina Horneff⁵, Lisa Tan^{5,6}, Michael Yeh⁷, Jens Panse⁸

Affiliations:

¹French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

²Department of Haematology, St James's University Hospital, Leeds, United Kingdom

³Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia

⁴Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA

⁵Swedish Orphan Biovitrum AB, Stockholm, Sweden

⁶Lisa Tan Pharma Consulting Ltd., Cambridge, UK

⁷Apellis Pharmaceuticals, Inc., Waltham, MA, USA

⁸Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany; Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany

Corresponding author:

Régis Peffault de Latour, French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Université Paris Cité, Saint-Louis Hospital, Paris 75010, France regis.peffaultdelatour@aphp.fr

Data access and data sharing statement All authors analyzed the data and had full access to all clinical trial data.

Data access will be granted in response to qualified research requests. Individual participant data will not be shared. All requests are evaluated by a cross-functional panel of experts within Sobi, and a decision on sharing will be based on the scientific merit and feasibility of the research proposal, maintenance of personal integrity, and commitment to publication of the results. To request access to study data, a data sharing request form (available on www.sobi.com) should be sent to medical.info@sobi.com.

Word count text: 2310 (max. 4000) Word count abstract: 206 (max. 250) Figure/Table count: 2/2 Number of references: 28

Key points:

- Most hemolysis events in difficult-to-treat PNH patients on pegcetacoplan were manageable without pegcetacoplan discontinuation
- Higher disease activity at baseline may indicate patients at increased risk of hemolysis

Abstract

Patients with paroxysmal nocturnal hemoglobinuria (PNH) experience complement-mediated intravascular hemolysis leading to anemia, fatigue, and potentially life-threatening thrombotic complications. Pegcetacoplan, a C3 inhibitor, demonstrated sustained improvements in hematological and clinical parameters in the Phase 3 PEGASUS trial in patients with PNH who remained anemic despite C5 inhibitor therapy. The current post-hoc analysis describes 26 hemolysis adverse events (AEs) experienced in 19 patients during pegcetacoplan therapy in PEGASUS and baseline patient characteristics potentially associated with increased hemolysis risk. Lactate dehydrogenase (LDH) $\ge 2 \times$ the upper limit of normal (ULN) was observed in 19 events, including 2 with LDH ≥10× ULN. All patients experienced decreased hemoglobin during hemolysis (mean decrease: 3.0 g/dL). In 16 events (62%) a potential complement-amplifying condition underlying the event could be identified. Hemolysis AEs led to study discontinuation in 5 patients. However, 17 of 26 (65%) hemolysis AEs were manageable without pegcetacoplan discontinuation. A greater proportion of patients with hemolysis AEs (n=19) had key characteristics of higher disease activity at baseline compared to patients without hemolysis AEs (n=61), namely higher-than-label eculizumab dose (53% vs 23%), detectable CH50 (74% vs 54%) and \geq 4 transfusions in the previous 12 months (68% vs 51%). These characteristics may be useful predictors of potential future hemolysis events. ClinicalTrials.gov identifier: NCT03500549

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, rare, and potentially life-threatening hematological disease¹ characterized by chronic complement-mediated intravascular hemolysis (IVH), thrombosis, and fatigue.² Complement C5 inhibitors eculizumab and ravulizumab have improved PNH patient outcomes and survival by reducing IVH and thrombosis risk.^{3–6} Despite this, 72-86% of patients remain anemic and approximately one third continue to require blood transfusions, mostly due to C3-mediated extravascular hemolysis (EVH).^{7–11}

Pegcetacoplan is the first complement C3 inhibitor approved by the FDA and EMA for the treatment of PNH.^{12,13} In the pivotal Phase 3 PEGASUS study in patients with PNH who remained anemic despite C5 inhibitor therapy, pegcetacoplan demonstrated superiority in change in hemoglobin level from baseline to 16 weeks as compared to eculizumab due to its broad control of IVH and emergent EVH under C5 inhibition.¹⁴ Further assessment of efficacy and safety of pegcetacoplan to 48 weeks demonstrated sustained improvements in hematological outcomes and quality of life measures.¹⁵

Breakthrough hemolysis events were first described in patients treated with C5 inhibitors when IVH reoccurred despite treatment.³ Breakthrough events while on C5 inhibition can be pharmacokinetic in nature and typically occur towards the end of a dosing interval.¹⁶ Alternatively, complement-amplifying conditions (CACs) such as infection, vaccination or surgery, can drive pharmacodynamic breakthrough despite adequate complement inhibitor dosing.^{16–19}

Adverse events (AEs) of hemolysis were reported by investigators in patients treated with pegcetacoplan in the PEGASUS study.^{14,15} The PEGASUS study enrolled a selection of eculizumab-treated patients with severe EVH, the majority requiring regular transfusions. Additionally, around a third of patients were on a higher-than-label dose of eculizumab prior to entry.¹⁴

This analysis aims to better describe hemolysis events under C3 inhibition to identify potential predictors associated with hemolysis during pegcetacoplan treatment to improve timely and adequate management.

Methods

Study design and population

PEGASUS (NCT03500549) was a Phase 3, randomized, open-label, multi-center, active-comparator controlled trial. The study design and results have been previously described.^{14,15} In this analysis, data from patients who experienced hemolysis events during the 48-week study period were investigated. Hemolysis events were not defined in the study protocol but were assessed based on AE reporting, as judged by the investigator (AEs coded to system organ class and preferred term using MedDRA Version 20.0).

The PEGASUS study was approved by the Institutional Review Board or Independent Ethics Committee at participating trial sites and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all patients.

Characterization of hemolysis events

To further characterize hemolysis events, changes in hemoglobin and lactate dehydrogenase (LDH) levels before and during the event were described, based on laboratory values that were sampled most proximal to the event. For pegcetacoplan, central and local laboratory values were collected. For values obtained at certified local laboratories, units and normal ranges were normalized to maintain consistency with the study's central laboratory (hemoglobin normal ranges 12.0-16.0 g/dL for female participants and 13.6-18.0 g/dL for male participants and LDH normal range 113–226 U/L). Potential CACs that were proximal to the time of the event were reviewed jointly by authors and analysis sponsors; these were identified either as an AE reported by the investigator or inferred from records of concomitant medications. The severity of hemolysis, its relationship to pegcetacoplan and study discontinuations due to hemolysis were also reviewed. Definitions that were considered when severity and relationship of AEs to study drug were evaluated by the investigators are included as a data supplement available with the online version of this article.

Evaluation of hemolysis risk

The key parameters of interest were baseline patient characteristics to assess disease activity, including higher-than-label eculizumab dose, detectable CH50 level while on eculizumab, and \geq 4 transfusions within 12 months prior to study entry.

Management of hemolysis

Management strategies for hemolysis AEs were not included in the PEGASUS study protocol. Based on preliminary clinical experience, dose adjustment of pegcetacoplan, red blood cell (RBC) transfusions to improve anemia-related symptoms, or acute administration of eculizumab to control IVH could be considered.²⁰

If a patient did not respond adequately to the twice weekly dose of pegcetacoplan (LDH levels >2× upper limit of normal [ULN]), dosing could be increased to 1080 mg up to every 3 days according to the current prescribing information.¹³ Benefit of increased dosing was defined as pegcetacoplan concentration change with a minimum of 1 month at increased dosing, demonstration of LDH decrease, resolution of hemolysis (as reported by the investigator) or no new events after dose escalation, and completion of study.

The PEGASUS study was approved by the Institutional Review Board or Independent Ethics Committee at participating trial sites and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all patients.

Results

Study population and baseline characteristics

In total, 19 of 80 patients (24%) treated with pegcetacoplan in PEGASUS experienced a hemolysis AE. Patient characteristics on entry into PEGASUS for patients with and without hemolysis events are presented in **Table 1**. At baseline, patients who experienced hemolysis AEs were older with a mean age of 54.5 years and the majority were male (63%) compared to those without a hemolysis event (47.0 years and 31%, respectively). Patients who experienced hemolysis AEs were more likely to have a history of thrombosis at baseline than those without a hemolysis event (42% and 28%, respectively) and had a higher mean CH50 level at baseline (19.7 and 5.4 U/mL, respectively).

Incidence and characterization of hemolysis on pegcetacoplan

Up to week 16 of the randomized controlled period (RCP), 4 patients (10%) on pegcetacoplan experienced hemolysis AEs as reported by the investigators.¹⁴ During the following 32-week open-label period (OLP) (weeks 17-48), 15 patients (19.5%) on pegcetacoplan experienced a hemolysis AE.¹⁵

The 19 patients with reported hemolysis AEs experienced 26 events (**Table 2**). Nineteen of 22 events with LDH values reported (86%) were associated with increased LDH (defined as LDH elevation $\ge 2 \times ULN^{21,22}$). Using the highest value recorded during each event, mean LDH increased from 324 U/L before hemolysis to 1128 U/L during hemolysis. Extremely high LDH levels ($\ge 10 \times ULN$) were an exception, occurring in only 2 patients (9%). No thrombotic events were reported in either of these patients. Using the lowest value recorded during each event, mean hemoglobin decreased from 11.3 g/dL before hemolysis to 8.3 g/dL during hemolysis. In 16 of the 26 hemolysis events (62%) a potential CAC, such as infection or vaccination, within 30 days of a hemolysis AE could be identified.

Fourteen of the 26 hemolysis events (54%) were considered moderate in severity. Hemolysis events led to study discontinuation in 5 patients, 3 during the RCP before study day 56 (LDH >1000 U/L for all; 2 with moderate severity; 1 patient received eculizumab to manage the event) and 2 during the OLP (LDH <1000 U/L for both). Three additional patients discontinued the study due to AEs unrelated to hemolysis (one pneumonitis 20 days before the hemolysis event, one fatal COVID infection and one sepsis) (**Table 2**). Seventeen of 26 (65%) hemolysis events were manageable without pegcetacoplan discontinuation.

Predictors of hemolysis

Patients with hemolysis AEs on pegcetacoplan in the PEGASUS study were associated with more key characteristics of higher disease activity at baseline than patients without hemolysis AEs (Figure 1). Over half of the patients (10 of 19) recording a hemolysis event were on a higher-than-label dose of eculizumab at study baseline. Of the 19 patients who experienced hemolysis AEs, 14 (74%) had detectable CH50 at baseline when compared to 54% of patients who did not experience hemolysis AEs. Thirteen patients (68%) in the hemolysis group and 31 (51%) in the non-hemolysis group required \geq 4 transfusions in the 12 months before study entry. The three characteristics were evaluated in different combinations; between 26% and 53% of patients with hemolysis AEs presented with 2 of 3 characteristics (Figure 1).

Management of hemolysis

Pegcetacoplan dose was increased in 13 patients (68%) that experienced a hemolysis AE during the PEGASUS study (Figure 2). Six (46%) of 13 patients showed benefit with the increased dosing, four (31%) did not demonstrate benefit, and three (23%) had insufficient duration of increased dosing to assess the effect of escalated dosing. Eleven patients (58%) required packed RBC transfusions and eculizumab was administered as rescue therapy in 4 patients (21%) in 4 different centers (Figure 2).

Discussion

This post-hoc analysis of patients from the Phase 3 PEGASUS study describes hemolysis events experienced during pegcetacoplan therapy. The identified characteristics of higher disease activity at baseline potentially associated with increased hemolysis risk may support physicians in identifying patients at risk and managing clinically relevant hemolysis events in pegcetacoplan-treated patients.

PEGASUS enrolled a study population with difficult-to-control disease. Despite receiving eculizumab treatment for a mean of 5 years, patients in the PEGASUS study had mean hemoglobin levels below the normal reference range and most required regular transfusions.¹⁴ Around a third of patients were on a higher-than-label dose of eculizumab prior to entry, suggesting a population prone to experiencing hemolysis. However, even in this patient population pegcetacoplan treatment was effective in managing the disease. Moreover, patients treated with pegcetacoplan did not have a higher risk for hemolysis events compared with eculizumab in the study. Up to week 16, more patients treated with eculizumab experienced hemolysis AEs (n=9) compared to pegcetacoplan (n=4).¹⁴ In addition, no hemolysis AE was reported during 26 weeks in the Phase 3 PRINCE study evaluating pegcetacoplan in complement inhibitor-naïve patients (46 patients treated with pegcetacoplan overall).²³

For nearly two-thirds of the reported hemolysis events a potential CAC could be identified. While hemolysis events in the context of eculizumab C5 inhibition have been identified as largely pharmacokinetic in nature,^{16,24} the mechanisms underlying events in pegcetacoplan-treated patients remain under investigation. A real-world study of compassionate use of pegcetacoplan in patients previously treated with eculizumab described 5 of 7 hemolysis events related to a CAC, with a mean LDH increase of 4.61× ULN for 6 of 7 hemolysis events.²⁵

Despite the greater proportion of PNH RBCs rendered susceptible to lysis due to the high efficacy of C3 inhibition,^{14,15} our analysis underlines that the majority of patients in the PEGASUS study did not experience severe acute hemolysis AEs as discussed in recent reviews of the PEGASUS data.^{1,16,26,27} Most hemolysis events (54%) were considered moderate in severity and 11 patients from this difficult-to-treat patient population continued pegcetacoplan treatment. Of note, management strategies for hemolysis AEs were not included in the PEGASUS study protocol. Therefore, the discontinuations of pegcetacoplan due to hemolysis AEs need to be interpreted with caution and might not necessarily be associated with the severity of the event.

High disease activity may confer an increased risk of hemolysis in a subgroup of patients with PNH on pegcetacoplan. Three characteristics of higher disease activity at baseline were identified, namely higher-than-label eculizumab dose, detectable CH50 and ≥4 transfusions in the previous 12 months, that may be useful predictors of potential future hemolysis events. Establishing measures of disease activity associated with hemolysis events, such as detectable CH50 at the onset of pegcetacoplan treatment, may allow early identification of patients at risk for such events. However, management will vary between centers.

Not all patients on proximal inhibition are at risk for hemolysis events. However, it is advised to monitor patients switching from C5 inhibitors to pegcetacoplan for signs of hemolysis. Patients and physicians should be alert to possible CACs and in the event of pharmacodynamic influence, the identified CAC should be treated in parallel with increased pegcetacoplan dosing per approved prescribing information.^{20,25} If a hemolysis event occurs, pegcetacoplan dose adjustment should be performed immediately. RBC transfusion or an extra dose of eculizumab may be considered if IVH is not controlled quickly. Acute intravenous or intensive subcutaneous pegcetacoplan as a new

approach for treatment of acute hemolysis events is currently being investigated as part of the longterm extension study (NCT03531255). Based on preliminary data, intensive intravenous of subcutaneous pegcetacoplan dosing is effective in managing acute hemolysis events in patients on pegcetacoplan.²⁸

Study limitations include the timing of laboratory sample collection. Although laboratory values were collected for patients receiving pegcetacoplan to build a comprehensive picture of hemolysis events, the collection of these samples did not necessarily coincide with the hemolysis AE. As a result, this analysis reviewed available laboratory values post-hoc and used values recorded most proximal to the actual event. A similar approach was used in assessing potential CACs underlying each hemolysis event, where a post-hoc review of investigator-reported AEs and concomitant medications may not have provided a comprehensive clinical picture of the patients described in this analysis. Further study limitations include the lack of additional laboratory data to better define the severity of the hemolysis AEs, as well as their relationship to CACs. Given the inclusion criteria of the PEGASUS study, the identified characteristics of high disease activity associated with a higher risk for hemolysis may only be applicable for a subset of patients with PNH. Finally, the study is descriptive in nature with no formal statistics to analyze the different patient populations.

In summary, while progress has been made in the management of hemolysis events during pegcetacoplan treatment, risk mitigation strategies continue to be necessary with a focus on patient and clinician education. Patients can remain on pegcetacoplan, with current prescribing information allowing for a pegcetacoplan dose increase from twice weekly to up to every 3 days in cases of LDH >2× ULN.^{12,13} Higher disease activity at baseline may confer an increased risk of a severe hemolysis event in a subgroup of patients with PNH on pegcetacoplan and further investigation into predictors of hemolysis events is warranted to augment current risk mitigation strategies.

Acknowledgements

The PEGASUS study was funded by Apellis Pharmaceuticals, Inc. The analysis was funded by Swedish Orphan Biovitrum AB. Medical writing support was provided by Miriam Souto of nspm ltd. (Meggen, Switzerland) and funded by Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals, Inc.

Authorship Contributions

The study was designed by the sponsor (Apellis Pharmaceuticals) and the academic authors. Trial investigators collected the data. R.P.L., M.G., R.J.K., J.S., C.C. R.H., L.T., M.Y, and J.P. (all authors) contributed to the analysis or interpretation of the data as well as revision of the manuscript. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol. Medical writing assistance was paid for by Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals, Inc. Manuscript review was conducted by Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals during the development process. Full editorial control of the manuscript was maintained by the authors, all of whom provided their final approval of the manuscript submitted for publication.

Disclosure of Conflicts of Interest

R. Peffault de Latour reports consultancy, honoraria, research funding with Alexion, Novartis, and Pfizer; research funding with Amgen; and consultancy and honoraria with Apellis Pharmaceuticals and Swedish Orphan Biovitrum AB. M. Griffin reports consultancy with BioCryst, Regeneron, and Swedish Orphan Biovitrum AB, speaker's fees from Alexion, AstraZeneca, Novartis, and Swedish Orphan Biovitrum AB, scientific advisory board member for Alexion, AstraZeneca, BioCryst, and Novartis. R.J. Kelly reports research support from Novartis and Swedish Orphan Biovitrum AB, consultancy with Swedish Orphan Biovitrum AB, speaker's fees from Alexion, Swedish Orphan Biovitrum AB, Jazz, Astellas, Otsuka, Amgen, Novartis and Biologix, scientific advisory board member for Alexion, Swedish Orphan Biovitrum AB, Jazz, Abbvie, Novartis and Roche. J. Szer reports research support from Alexion, Apellis Pharmaceuticals, Novartis, Ra Pharma, Sanofi-Genzyme, consultancy with Biocryst, speaker's fees from Alexion, Novartis, Swedish Orphan Biovitrum AB, scientific advisory board member for Link Pharmaceuticals, Novartis, Sanofi-Genzyme, Swedish Orphan Biovitrum AB. C. de Castro reports research funding from Alexion Pharmaceuticals, and Apellis Pharmaceuticals, consultancy at Apellis Pharmaceuticals, honoraria from Novartis, Alexion Pharmaceuticals, Biocryst, and Apellis Pharmaceuticals. R. Horneff is currently employed by Swedish Orphan Biovitrum AB and hold company shares. L. Tan is a consultant to Swedish Orphan Biovitrum AB. M. Yeh is currently employed by Apellis Pharmaceuticals, Inc. and hold company shares. J. Panse reports consultancy, honoraria, membership on an entity's Board of Directors or advisory committees with Apellis Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Grunenthal, and MSD; consultancy, membership on an entity's Board of Directors or advisory committees with Amgen; speakers bureau with Chugai and Pfizer; and membership on an entity's Board of Directors or advisory committees, speakers bureau with Alexion, Boehringer Ingelheim and Novartis.

References

- 1. Peffault De Latour R, Hosokawa K, Risitano AM. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. *Semin Hematol*. 2022;59(1):38-46.
- 2. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. *Nat Rev Dis Primers*. 2017;3:17028.
- Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2008;111(4):1840-1847.
- 4. Kulasekararaj AG, Hill A, Langemeijer S, et al. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. *Eur J Haematol*. 2021;106(3):389-397.
- 5. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood*. 2011;117(25):6786-6792.
- Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2007;110(12):4123-4128.
- 7. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. *Blood*. 2009;113(17):4094-4100.
- 8. McKinley C, Richards S, Munir T, et al. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. *Blood*. 2017.
- 9. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. *Ann Hematol*. 2022;101(2):251-263.
- Panse J, Sicre de Fontbrune F, Burmester P, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life. *Eur J Haematol*. 2022;109(4):351-363.
- 11. Sicre de Fontbrune F, Burmester P, Piggin M, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. *Hematology*. 2022;27(1):1140-1151.
- EMPAVELI (pegcetacoplan) US Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215014s002lbl.pdf. Accessed 8 March 2023.
- 13. Aspaveli (pegcetacoplan) EMA Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/aspaveli-epar-product-information_en.pdf. Accessed 15 November 2023.
- 14. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. *N Engl J Med*. 2021;384(11):1028-1037.
- 15. Peffault de Latour R, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, openlabel, phase 3, active-comparator, controlled trial. *Lancet Haematol*. 2022;9(9):e648-e659.
- Risitano AM, Peffault De Latour R, Marano L, Frieri C. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. *Semin Immunol*. 2022;59:101618.
- 17. Brodsky RA. Eculizumab: another breakthrough. *Blood*. 2017;129(8):922-923.

- 18. Miyasaka N, Miura O, Kawaguchi T, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. *Int J Hematol*. 2016;103(6):703-712.
- 19. Harder MJ, Kuhn N, Schrezenmeier H, et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. *Blood*. 2017;129(8):970-980.
- 20. Hillmen P, Risitano AM, Peffault de Latour R. Pegcetacoplan versus Eculizumab in PNH. Reply. *New England Journal of Medicine*. 2021;385(18):1723-1726.
- 21. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. *Blood*. 2021;137(10):1304-1309.
- 22. Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2021;106(1):230-237.
- 23. Wong RSM, Navarro-Cabrera JR, Comia NS, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. *Blood Adv*. 2023;7(11):2468-2478.
- 24. Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. *Frontiers in Immunology*. 2019;10:1157.
- 25. Griffin M, Muus P, Munir T, et al. Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria. *Blood*. 2023;141(1):116-120.
- 26. Notaro R, Luzzatto L. Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. *New England Journal of Medicine*. 2022;387(2):160-166.
- 27. Risitano AM, Frieri C, Urciuoli E, Marano L. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. *Immunol Rev.* 2023;313(1):262-278.
- 28. Griffin M, Kelly RJ, Panse JP, et al. Management of Acute Breakthrough Hemolysis with Intensive Pegcetacoplan Dosing in Patients with PNH. *Blood Adv*. 2024.

Tables

Table 1. Baseline characteristics for PEGASUS patients with and without hemolysis events.

	Patients with hemolysis event (n=19)	Patients without hemolysis event (n=61)
Age, years		
Mean (range)	54.5 (28-78)	47.0 (19-81)
>65, n (%)	7 (37)	10 (16)
Sex, n (%)		
Female	7 (37)	42 (69)
Body mass index, mean (SD), kg/m ²	27.5 (4.5)	26.0 (4.2)
No transfusions in previous 12 months, n (%)	4 (21)	16 (26)
≥4 transfusions in previous 12 months, n (%)	13 (68)	31 (51)
History of thrombosis, n (%)	8 (42)	17 (28)
On-label eculizumab dose at screening (900 mg every 2 weeks), n (%)	9 (47)	47 (77)
Higher-than-label eculizumab dose at screening (>900 mg every 2 weeks), n (%)	10 (53)	14 (23)
1200 mg every 2 weeks*	9 (47)	13 (21)
1500 mg every 2 weeks	1 (5)	1 (2)
Hemoglobin, mean (SD), g/dL	8.8 (1.0)	8.6 (1.0)
Lactate dehydrogenase, mean (SD), U/L	305.6 (212.6)	275.2 (211.7)
Complement CH50, mean (SD), U/mL	19.7 (27.6)	5.4 (16.0)
Detectable complement CH50, n (%)	14 (74)	33 (54)

* One patient in the pegcetacoplan group received 900 mg of eculizumab every 11 days.

Table 2. Characterization of hemolysis in patients on pegcetacoplan.

Patient	Study group	Baseline Hb, g/dL	Baseline LDH, U/L	Baseline CH50, U/mL	ECU starting dose, mg	Transfusions ≤12 months before screening	History of thrombosis	Study days (D) of hemolysis event/ Study period	Hb before hemolysis event*, g/dL	Hb during hemolysis event, g/dL	LDH before hemolysis event*, U/L	LDH during hemolysis event, U/L	Severity/ Relationship to PEG	Potential CAC	Discontinuation
1	ECU-to-PEG	i 8.1	279	22	900	0	No	D315-318/ OLP	12.4	10.6	214	650	Moderate/ not related	Febrile infection	No
						0		D318-NR/ OLP	10.6	8.8	650	517	Severe/ not related	Febrile infection	NO
2	PEG-to-PEG	8.6	158	0	1200	0	No	D49–56/ RCP	10.6	8.5 [†] –7.2	121	1100 ⁺ -813	Moderate/ related	No	Yes, due to hemolysis
3	ECU-to-PEG	8.6	228	0	1200	0	No	D281-309/ OLP	13.3	10.4-12.4	220	658-189	Moderate/ not related	Infection	No
4	PEG-to-PEG	9.7	197	16	1200	0	Yes	D242-316/ OLP	14.2	6.6-11.3	162	815-225	Severe/ not related	URT infection	No
5	PEG-to-PEG	10.6	202	20	1200	2	No	D140-155/ OLP	15.1	13.9-14.5	190	1050-184	Severe/ not related	Infection	No
	PEG-to-PEG	7.4	250	2	1500	2	Yes	D42-47/ RCP	12.2	10.9–6.4	149	$\begin{array}{c} \textbf{1539-}\\ \textbf{2481}^{^{\dagger}}\end{array}$	Moderate/ not related	No	Yes, due to hemolysis
0		7.4	250	3				D47–53/ RCP	12.2	NR	1539	NR	Severe/ not related	No	
7	ECU-to-PEG	8.2	192	33	900	4	Yes	D194-NR/ FU	11.1	NR	119	NR	Moderate/ not related	No	Yes, due to pneumonitis 20 days before hemolysis
8	PEG-to-PEG	6.0	317	1	900	5	No	D36–39/ RCP	10.9	7.2 ⁺ -4.8	183	4147 ⁺	Moderate/ related	No	Yes, due to hemolysis
9	PEG-to-PEG	7.3	301	19	900	5	Yes	D296-305/ OLP	11.6	5.9	191	NR	Severe/ not related	COVID infection	Yes, due to COVID infection (fatal)
10	PEG-to-PEG	9.0	285	0	1200	5	Yes	D56-224/ RCP & OLP	11.5	11.8-9.4	373	754-883	Moderate/ not related	No	No
11	PEG-to-PEG	о <i>л</i>	227	0	1200	5	No	D225-253/ OLP	11.0	10.4-9.7	150	363-205	Moderate/ not related	URT infection	Voc. duo to consis
11		8.4				5		D268-289/ OLP	9.7	NR	205	1133	Moderate/ not related	Sepsis	res, ude to sepsis
12	ECU-to-PEG	84	236	5 1	900	6	No	D149-156/ OLP	13.9	6.6	113	NR	Severe/ not related	Surgery, sepsis	No
								D185-245/ OLP	6.0	6.4	438	1184	Severe/ not related	Pneumonia	
13	ECU-to-PEG	10.2	1383	90	900	6	Yes	D191-218/ OLP	13.1	6.4	173	1166	Moderate/ not related	Pancreatitis	No
								D310-NR/	11.0	9.5 [‡]	891	2197 [‡]	Moderate/	No	

							OLP			not related					
14	ECU-to-PEG	9.1	175	4	900	7	No	D197–322/ OLP	11.3	8.6–11.6	207	790–222	Severe/ possibly related	No	Yes, due to hemolysis
15 ECU-		7.0	204	0	1200	0	Yes	D192–199/ OLP	11.9	7.3–10	98	460–505	Severe/ not related	Infection	Yes, due to
	ECO-to-PEG	7.9	204	0	1200	٥		D275–283/ OLP	8.3	8.9	451	840	Severe/ not related	UT infection	hemolysis
16	PEG-to-PEG	8.9	484	90	1200	11	No	D168-NR/ OLP	8.4	8.5	524	848	Moderate/ not related	Diarrhea	No
17	ECU-to-PEG	10.4	392	12	900	19	No	D254-NR/ OLP	7.9	9.1	323	397	Moderate/ not related	No	No
18	PEG-to-PEG	8.7	426	37	900	21	Yes	D182-219/ OLP	11.5	9.2	180	246	Severe/ not related	Sepsis	No
19	PEG-to-PEG		201	27	1200	20	N	D106-140/ RCP	12.9	7.0-12.1	180	652-352	Severe/ not related	Vaccination	
		11.1	281	27	1200	30	NO	D236-NR/ OLP	11.7	10.4	376	2203	Moderate/ not related	No	NO

Hemolysis events presented in this table were defined using MedDra preferred terms. Severity of events was defined as follows: Mild – Events resulted in mild or transient discomfort, not requiring intervention or treatment; does not limit or interfere with daily activities; Moderate - Event is sufficiently discomforting so as to limit or interfere with daily activities; may require interventional treatment; Severe - Event results in significant symptoms that prevent normal daily activities; may require hospitalization or invasive intervention. Severity of hemolysis event and relationship to study drug are based on investigator report. Hemoglobin limit ranges 12.0-16.0 g/dL for female participants and 13.6-18.0 g/dL for male participants; LDH limit range 113–226 U/L. * Most recent available measurement before event. * Values recorded by a local laboratory. * In patient 13, these 'during event' laboratory values were recorded one day prior to the reported start date of the adverse event of hemolysis, but were deemed the most appropriate measurements to use. CAC, complement-amplifying condition; CH50, total complement function; D, day; ECU, eculizumab; Hb, hemoglobin; LDH, lactate dehydrogenase; NR, not reported; OLP, open-label period; PEG, pegcetacoplan; RCP, randomized controlled period; UT, urinary tract; URT, upper respiratory tract.

Figure legends

Figure 1. Predictors of hemolysis in patients with and without hemolysis events.

Assessment of key characteristics of higher disease activity at PEGASUS study baseline in patients with and without hemolysis events: Higher-than-label eculizumab dose at screening (>900 mg every 2 weeks, ≥4 transfusions within 12 months prior to study entry, and detectable CH50 levels while on eculizumab treatment. ECU, eculizumab.

Figure 2. Management of hemolysis adverse events in PEGASUS.

* If a patient did not respond adequately to the twice weekly dose of pegcetacoplan (LDH levels ≥2 x ULN) dosing could be increased to 1080 mg every third day according to the prescribing information¹³. AE, adverse event; CAC, complement-amplifying conditions; ECU, eculizumab; HAE, hemolysis adverse event; LDH, lactate dehydrogenase; PEG, pegcetacoplan; RBC, red blood cell; ULN, upper limit of normal.



Downloaded from http://ashuthiteations.com/active-pdf/doi/10.1182/bloodadvances.com/active-com R Suspected CAC



Figiytae2.